Events in 2023

Genetics and the Fertility Clinic

Health inequalities are unfair and avoidable differences in health across the population, and between different groups within society. Health inequalities arise because of the conditions in which we are born, grow, live, work and age. These conditions influence our opportunities for good health, and how we think, feel and act, and this shapes our mental health, physical health, and wellbeing. The COVID-19 shone harsh light on the pre-existing health inequalities which persist in our society. It has become increasingly clear that COVID-19 has had a disproportionate impact on many who already face disadvantage and discrimination. The impact of the virus has been particularly detrimental on people living in areas of high socio-economic deprivation, on people from Black, Asian and minority ethnic minority communities and those with a learning disability.

In England, there is a 19-year gap in healthy life expectancy (whether we experience health conditions or diseases that impact how long we live in good health) between the most and least affluent areas of the country, with people in the most deprived neighbourhoods, certain ethnic minority and inclusion health groups getting multiple long-term health conditions 10 to 15 years earlier than the least deprived communities, spending more years in ill health and dying sooner.

The Biomedical Sciences have a significant and pivotal role to play in narrowing the health inequalities gap through Research, Innovation and Life Sciences and its extensive reach across clinical practice within the NHS.

Crimean-Congo haemorrhagic fever is the most widely distributed hard tick-borne disease in the world.

Different factors, such as a better knowledge of the disease, but also trade, modifications of the migratory bird routes and, probably, the climate change are favouring its increase.

The example of the emergence in Spain will be reviewed.

Implementing a new laboratory IT system and how to avoid the pitfalls

Highlighting the value of diagnostics, promoting the diagnostic workforce and improving diagnostic services

Sustainability is the balance between the environment, equity, and economy. It is well documented that our changing climate has severe implications for public and planetary health. As healthcare professionals, we have a responsibility to consider the way we practice and try to reduce any negative impacts of our practice.

This workshop looks at the carbon footprint of the lab and discusses what processes and practices can be adapted to reduce the carbon footprint of pathology practice. It explores the barriers to change and areas to target for improvement.

Overcoming challenges to passing cervical cytology exams

This talk will focus on how level 2 and level 4 apprenticeships can help to engage in widening participation and EDI agenda as well as create an entry level workforce pipeline and staff that can be grown through apprenticeship progression routes into the Biomedical science profession.

Motivating, training and developing on multiple sites – the Scarborough, Hull, York Pathology Service workforce journey

Digital imaging for remote viewing to enable reporting is becoming increasingly prevalent in the NHS cellular pathology services. Sea change levels of improvement in the technology that enables digital image acquisition, viewing, transfer and storage has allowed its widespread deployment and adoption and concomitant to this has been the development of software applications to enable the analysis of those digital images for a huge variety of reasons.

In my talk I will discuss the application of digital image analysis to the scans of the slides that we assess as part of our routine external quality assessment (EQA) workload. Both as aids to improve the information and the accuracy of that information e.g., in the assessment of the proliferation marker Ki-67 in breast cancer to improve its use as a prognostic marker, and as a tool to verify and quality control our own processes and EQA materials e.g., the measurement of reproducibility and homogeneity in tissue and cell line samples used in the assessment of PD-L1 immunohistochemistry staining in non-small cell lung cancer.